Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2020 1
2021 1
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O. Wang E, et al. Among authors: chaudhry s. N Engl J Med. 2022 Feb 24;386(8):735-743. doi: 10.1056/NEJMoa2114110. N Engl J Med. 2022. PMID: 35196427 Free PMC article.
Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
Totiger TM, Chaudhry S, Musi E, Afaghani J, Montoya S, Owusu-Ansah F, Lee S, Schwartz G, Klimek V, Taylor J. Totiger TM, et al. Among authors: chaudhry s. J Cell Mol Med. 2023 Feb;27(4):587-590. doi: 10.1111/jcmm.17667. Epub 2023 Feb 1. J Cell Mol Med. 2023. PMID: 36722323 Free PMC article.
Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia.
Brabson JP, Leesang T, Yap YS, Wang J, Lam MQ, Fang B, Dolgalev I, Barbieri DA, Strippoli V, Bañuelos CP, Mohammad S, Lyon P, Chaudhry S, Donich D, Swirski A, Roberts E, Diaz I, Karl D, Dos Santos HG, Shiekhattar R, Neel BG, Nimer SD, Verdun RE, Bilbao D, Figueroa ME, Cimmino L. Brabson JP, et al. Among authors: chaudhry s. Cell Rep. 2023 Jan 31;42(1):112027. doi: 10.1016/j.celrep.2023.112027. Epub 2023 Jan 23. Cell Rep. 2023. PMID: 36848231 Free PMC article.
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
Bewersdorf JP, Stahl M, Taylor J, Mi X, Chandhok NS, Watts J, Derkach A, Wysocki M, Lu SX, Bourcier J, Hogg SJ, Rahman J, Chaudhry S, Totiger TM, Abdel-Wahab O, Stein EM. Bewersdorf JP, et al. Among authors: chaudhry s. Leukemia. 2023 Dec;37(12):2512-2516. doi: 10.1038/s41375-023-02050-4. Epub 2023 Oct 9. Leukemia. 2023. PMID: 37814121 Free PMC article. Clinical Trial. No abstract available.
Break Scrub to Take That Phone Call?
Schirmer A, Swan C, Hughes SJ, Vasilopoulos T, Oli M, Chaudhry S, Gravenstein N, Giordano C. Schirmer A, et al. Among authors: chaudhry s. J Am Coll Surg. 2018 Jun;226(6):1117-1121. doi: 10.1016/j.jamcollsurg.2018.03.002. Epub 2018 Mar 8. J Am Coll Surg. 2018. PMID: 29524662
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).
Nguyen N, Chaudhry S, Totiger TM, Diaz R, Roberts E, Montoya S, Pardo G, Pardo A, Afaghani J, Affer M, Jahn J, Bradley T, Maura F, Kazandjian D, Bilbao D, Chapman J, Landgren O, Hoffman J, Taylor J. Nguyen N, et al. Among authors: chaudhry s. NPJ Precis Oncol. 2022 Oct 19;6(1):73. doi: 10.1038/s41698-022-00315-2. NPJ Precis Oncol. 2022. PMID: 36261486 Free PMC article.
12 results